Zealand and Roche Share ZUPREME-1 Petrelintide Data

Phase 2 data for Zealand and Roche's petrelintide was shared at the ADA 2026 Scientific Sessions.

At the 2026 American Diabetes Association (ADA) Scientific Sessions in New Orleans, Zealand Pharma and Roche announced highly anticipated results from their Phase 2 ZUPREME-1 trial. The clinical trial evaluated petrelintide, an investigational once-weekly amylin analog designed to support long-term weight management. These findings offer an exciting look at a new class of weight loss drugs that could provide a highly effective, better-tolerated alternative to traditional treatments.

How Do Petrelintide and the Amylin Pathway Work?

While popular weight-management options like semaglutide treatment programs rely on mimicking the GLP-1 gut hormone to suppress appetite, petrelintide takes a different route. It mimics amylin, a natural hormone co-secreted with insulin by the pancreas that regulates how full you feel after a meal. By targeting this separate pathway, petrelintide helps patients curb hunger and manage their weight without triggering the severe nausea often linked to GLP-1 therapies.

What Weight Loss Results Did the ZUPREME-1 Trial Reveal?

The Phase 2 ZUPREME-1 study tracked 493 adults living with obesity or overweight, none of whom had type 2 diabetes, over 42 weeks. The results showed that petrelintide delivers powerful weight loss that scales with the dose. Patients taking the highest dose achieved an impressive average body weight reduction of 10.7%, compared to a tiny 1.7% loss in the placebo group.

Key clinical findings from the 42-week study include:

• An average body weight reduction of up to 10.7% in the high-dose group.
• Statistically significant weight reduction compared to the placebo cohort.
• A continuous weight-loss trajectory, suggesting that participants would likely continue to lose weight beyond 42 weeks.

Why is Petrelintide's Tolerability Profile So Unique?

Beyond weight loss, the most remarkable feature of petrelintide is its clean tolerability profile, which researchers described as "placebo-like." For patients who struggle with the side effects of existing weight loss drugs, this could represent a massive breakthrough. In the high-dose group, there were no reports of vomiting and absolutely no patients stopped the trial due to gastrointestinal issues.

Furthermore, an incredible 98% of patients in the highest-dose group successfully completed their dose escalation to reach the target maintenance dose. This high completion rate suggests that petrelintide is easy for patients to stay on, reducing the risk of treatment interruptions. This is a significant improvement over traditional therapies where side effects frequently lead to early discontinuation.

What Does Amylin-Based Weight Loss Mean for Patients?

The arrival of amylin-based therapies could reshape clinical weight management by offering patients personalized treatment choices. Individuals who experience severe gastrointestinal distress on GLP-1 receptor agonists may soon have a powerful, well-tolerated alternative. Doctors also discussed the potential of combining petrelintide with GLP-1 agonists to amplify weight loss while keeping side effects manageable.

For patients navigating their current weight-loss options, understanding the landscape is key. If you are exploring medical weight management, you can view current pricing to compare existing FDA-approved options and discuss them with your doctor.

What Are the Next Steps for Petrelintide's Development?

Buoyed by these positive results, Zealand Pharma and Roche plan to advance petrelintide into large-scale Phase 3 clinical trials in the second half of 2026. In addition, the companies will launch a Phase 2 trial in mid-2026 combining petrelintide with Roche's dual GLP-1/GIP receptor agonist, enicepatide (CT-388). These upcoming studies will help determine if combination therapies can deliver even greater weight loss while keeping patient comfort high.

This article is for informational purposes only and is not medical advice. Consult your healthcare provider before starting any weight loss medication or treatment.